John Lambert elect­ed chair­man of Mucosis

Dutch biotech­nol­o­gy com­pa­ny Mucosis B.V. announced today that John Lambert was elect­ed as mem­ber and chair of its Supervisory Board. Having held var­i­ous key posi­tions at phar­ma­ceu­ti­cal and biotech com­pa­nies in both the United States and Europe, Mr. Lambert brings excep­tion­al vac­cine indus­try expe­ri­ence to Mucosis.

From 1998 to 2000 Mr. Lambert was President at Aventis Pasteur MSD, a vac­cine joint ven­ture estab­lished between Aventis (now sanofi-aven­tis Group) and Merck & Co, Inc. Subsequently, from 2001 to 2005, he served as President of Chiron Vaccines (now Novartis Vaccines). Mr. Lambert was a non-exec­u­tive Director at Acambis Plc (U.K.), chair­man of the Conseil d’Administration of Farmaprojects S.A. (Spain), non-exec­u­tive chair­man of Cambridge Biostability Ltd. (U.K.) and advi­sor for Crucell N.V. (Netherlands) on acqui­si­tions and strat­e­gy. He is cur­rent­ly Board Director of Novavax Inc. (U.S.A.).

“I look for­ward to join­ing the Supervisory Board of this excit­ing com­pa­ny,” com­ment­ed Mr. Lambert. “Mucosis is on track to suc­cess­ful­ly devel­op Mimopath™-based vac­cines as an inno­v­a­tive approach to meet­ing world­wide health needs. I believe that this tech­nol­o­gy holds great poten­tial.”

Govert Schouten, Chief Executive Officer of Mucosis, added: “We are very hap­py to wel­come an indus­try pro­fes­sion­al of such cal­iber and expe­ri­ence. Mr. Lambert’s exper­tise will be impor­tant for our company’s abil­i­ty to build val­ue.”

Leave a Reply

Your email address will not be published. Required fields are marked *